Harmony Biosciences Holdings (HRMY) opened Q1 2026 with total revenue of US$215.4 million and basic EPS of US$0.56, setting a clear reference point against a trailing twelve month EPS of US$2.53 on US$899.1 million of revenue. Over recent quarters the company has seen quarterly revenue move from US$184.7 million in Q1 2025 to a peak of US$243.8 million in Q4 2025, while basic EPS has shifted from US$0.79 to US$0.39 over the same span. This puts the latest print into sharper context for investors weighing the balance between revenue scale and earnings power.

See our full analysis for Harmony Biosciences Holdings.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the prevailing narratives around Harmony Biosciences Holdings, and where those stories might need a rethink.

Margins Under Pressure At 16.2%

• Trailing twelve month net margin sits at 16.2%, compared with 20.5% in the prior year on US$899.1 million of revenue and US$145.6 million of net income.
• Bears focus on this margin compression as a sign that future profitability could be harder to sustain. However, the company still reports US$145.6 million of trailing net income and positive EPS of US$2.53, which shows:
  • Profitability remains positive even with the lower margin, so the concern is about future direction rather than a current loss.
  • Any further margin movement is likely to be watched closely against rising R&D and commercialization spend highlighted in the cautious narrative.

P/E Of 12.5x Versus Industry 16.7x

• At a share price of US$31.42 and trailing EPS of US$2.53, Harmony trades on a P/E of about 12.5x, below the cited US pharmaceuticals industry average of 16.7x and peer average of 16.5x.
• Bulls argue this discount, alongside a DCF fair value of US$203.67, points to meaningful upside in the story. The current earnings profile creates a mixed picture because:
  • Trailing earnings are described as high quality with Harmony having become profitable over the past five years, which fits a bullish view that the business model can support ongoing profits.
  • At the same time, trailing twelve month earnings have declined versus the prior year and margins moved from 20.5% to 16.2%, which gives bears a concrete set of numbers to justify some of the caution despite the low P/E.

Some investors will want to see how this valuation gap lines up with the more optimistic earnings path in the bullish narrative before deciding how to interpret the P/E discount and DCF fair value gap.🐂 Harmony Biosciences Holdings Bull Case

Forecast Growth Trails Market Averages

• Consensus figures in the data show expected earnings growth of about 7.9% per year and revenue growth of about 5.5% per year, both below the referenced US market averages of 16.4% for earnings and 11.4% for revenue.
• Skeptics point to these below market growth rates to question how much multiple expansion is realistic, especially with key risks around WAKIX concentration and pricing, because:
  • The cautious view highlights heavy reliance on a single product and potential pressure from payers and new therapies, which would matter more if growth is already tracking below the broader market.
  • If margins stay closer to the recent 16.2% level rather than the higher levels in the narratives, bears see less room for earnings to stretch into the higher targets discussed in more optimistic scenarios.

Readers who lean toward the more cautious narrative often zero in on these sub market growth forecasts and margin trends when deciding whether the valuation discount compensates for concentration and pricing risks.🐻 Harmony Biosciences Holdings Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Harmony Biosciences Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing both the bullish and cautious angles, the real question is what you make of the risk reward trade off in front of you. Move quickly, review the numbers that matter most, and then pressure test your view against the 3 key rewards

See What Else Is Out There

Harmony Biosciences Holdings faces margin compression, sub market earnings and revenue growth forecasts, and heavy reliance on a single product, which together create a tighter risk reward profile.

If those pressures make you want a smoother ride, check out 72 resilient stocks with low risk scores to quickly zero in on companies with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.